Praziquantel compounds for treating diseases due to...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/4965 (2006.01) A61K 31/495 (2006.01) A61P 33/00 (2006.01)

Patent

CA 2409926

Disclosed herein are compositions and methods of treating therapeutically, or metaphylactically infected mammals susceptible to, or infected mammals suffering from parasitic neurologic or abortigenic diseases such as Sarcocystis, Neosporosis or Toxoplasmosis or Isosporosis that are treatable with a praziquantel compound by administering thereto a composition containing a pharmaceutically effective amount of praziquantel or derivative thereof, including metaphylactic and single high dose treatment regimens.

L'invention concerne des compositions et des procédés pour le traitement thérapeutique ou métaphylactique des maladies neurologiques ou abortigéniques, déjà déclarées ou pouvant l'être, chez des mammifères, à partir de parasites du type Sarcocystis, Neospora, Toxoplasma ou Isospora. On administre des composés de praziquantel via une composition renfermant ce type de composé, ou un dérivé, en quantité pharmaceutiquement efficace, y compris les régimes de traitement à dose métaphylactique et unique élevée.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Praziquantel compounds for treating diseases due to... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Praziquantel compounds for treating diseases due to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Praziquantel compounds for treating diseases due to... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1448979

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.